atezolizumab,bevacizumab
roche
['bevacizumab', 'atezo', 'platinum', 'atalante', 'ovarian']
#esmo2022 the addition of the pd-l1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting in relapsed platinum-sensitive ovariancancer: the atalante/ov29 trial.participation of 
Spanish Ovarian Cancer Research Group (GEICO). Grupo Español de Investigación en Cáncer de Ovario y Tumores Ginecológicos. #cancerginecológico #GynCancer